Daniel Boden, Md Email & Phone Number
Who is Daniel Boden, Md? Overview
A concise factual answer block for searchers comparing this professional profile.
Daniel Boden, Md is listed as Pharmaceutical / Biotech Research Discovery Leader | Drive preclinical discovery programs to move swiftly into early development at Addition Therapeutics, based in San Francisco Bay Area, United States. AeroLeads shows a matched LinkedIn profile for Daniel Boden, Md.
Daniel Boden, Md previously worked as Senior Director at Addition Therapeutics and Director at The Janssen Pharmaceutical Companies Of Johnson & Johnson. Daniel Boden, Md holds Doctor Of Medicine (Md) from University Of Düsseldorf.
Email format at Addition Therapeutics
This section adds company-level context without repeating Daniel Boden, Md's masked contact details.
Review company-level records connected to Daniel Boden, Md before choosing the right outreach path.
About Daniel Boden, Md
Biotech and Pharmaceutical R&D leader with proven experience delivering milestones and goals on time as a scientific thought leader and research innovator, driving biology, virology, and immunology research operations. Redirect project success, utilizing analytics and troubleshooting to redefine trajectory.Lead highly productive teams by creating a motivational, collegial, open, and trustful working environment. Collaborate with cross-therapeutic teams to develop strategies and solutions while leading and managing research teams. Specialize in molecular and cell engineering, mRNA therapeutics, pharmacology and immunology.Promote Scientific Excellence | Innovative Problem Solving | Provide Leadership and Strategic VisionExcellent Interpersonal Skills | Establish and Maintain Relationships with External CollaboratorsDefine Therapeutic and Research Strategy Roadmap | Laboratory Operations Oversight
Daniel Boden, Md's current company
Company context helps verify the profile and gives searchers a useful next step.
Daniel Boden, Md work experience
A career timeline built from the work history available for this profile.
Director
Head of Molecular and Cellular Biology leading various research projects pertaining to HIV and HBV cure.Leads several mRNA therapeutic / vaccine preclinical programs.• Directed establishment of a rhinovirus in vivo pharmacology model by in vivo evolution.• Guides assay development and screening / profiling efforts of ASO/siRNAs for immunomodulatory targets.• Provided cross-functional leadership for various programs at Janssen BioPharma, delivering expert guidance on chronic HIV and HBV infection.• Investigated self-amplifying RNA vaccines.• Designed and explored multicistronic Ad26 vectors expressing multiple antigens.• Directed latency reversal agent (LRA) program for HIV cure identifying new LRA [Ref].• Designed and production of rAAV, delivering HBV and NTCP receptor in mice and NHPs.• Evaluated various therapeutic vaccine modalities, resulting in portfolio entry of therapeutic mRNA vaccine for chronic HBV.• Explored CRISP/Cas9 gene editing approaches for HBV cure.• Developed HDV ribozyme reporter screening assay.• Established SELEX aptamer platform for immune checkpoint inhibition.
Senior Principal Scientist
Group leader of therapeutic HBV vaccine program and directed several checkpoint inhibitor programs. Key responsible to develop innovative molecular assays for HBV antiviral program.• Developed therapeutic DNA vaccine for chronic HBV infection [in Phase 1b].• Developed genetic adjuvant for chronic infections and cancer therapy [patent pending].• Member of the HBV Research Strategy Team and the eCDT.• CRISP/Cas9 engineering of knock-in and knock-out cell lines.• Expert consultant for lentiviral transgene delivery technology.• Established critical assays, identifying new targets for eradication of chronic HBV infection.• Served as internal expert on virology and immunology projects, producing new project proposals and overseeing collaborative research efforts with external partners
Principal Scientist
Group leader of HIV latency/cure program. Supervised research team including 8 scientists.• Established panel of complex assay systems to screen, identify, and profile candidate hits for HIV cure.• Supervised 700K screening campaign for small molecule latency reversal compounds.• Served as expert in lentiviral and T-cell engineering.• Achieved patent publication of a new molecule with unparalleled activity for HIV eradication.• Directed various external research collaborations.• Coordinated conception and design of innovative screening assay for molecules against respiratory viruses. • 500K library compound screen resulted in promising candidate hits that were further pursued.• Honored with Janssen Research Innovation Award.
Principal Investigator Hiv-1 Research
Drafted and pursued grants, conceptualized new project opportunities, and led 2 research teams with 10 members. Evaluated and translated team results.• Awarded 3 separate National Institute of Health (NIH) grants, resulting in research that solidified center’s leadership role in HIV MDR research.• Conceptualized and launched programs using commensal bacteria as microbicide against HIV.
Assistant Professor
Launched virology laboratory operations, prepared grant proposals as well as manuscripts, and sourced international collaborative efforts for research opportunities.• Awarded 2 research grants (AmFAR and CFAR) and named 1st ever group to demonstrate viral escape of HIV-1 to RNA interference using rAAV-2 gene therapy vector delivery.
Research Fellow Virology
Oversaw laboratory research operations within clinical virology. Executed implementation of new technologies and assays and drafted proposals for new research opportunities.• Gained experience in clinical and diagnostic virology research with specialization in Hantavirus diagnosis, pathology, and epidemiology.
Postdoctoral Research Fellow
Developed experience and expertise in HIV-1 virology with particular specialization in drug resistance as well as knowledge regarding molecular virology, biology and immunology. Published multiple peer-reviewed work on HIV-1 drug resistance.
Postdoctoral Research Fellow
Key role in researching and publishing work in molecular virology with focus on JC virus pathogenesis in HIV-1 infected patients.
Daniel Boden, Md education
Doctor Of Medicine (Md)
Dissertation In Biochemistry
Doctor Of Medicine (Md), Residency Infectious Diseases
Doctor Of Medicine - Md, Residency Microbiology
Bachelor Of Science - Bs
Bachelor Of Arts (Ba), Biology, General
Postdoctoral Research Fellow, Virology
Frequently asked questions about Daniel Boden, Md
Quick answers generated from the profile data available on this page.
What company does Daniel Boden, Md work for?
Daniel Boden, Md works for Addition Therapeutics.
What is Daniel Boden, Md's role at Addition Therapeutics?
Daniel Boden, Md is listed as Pharmaceutical / Biotech Research Discovery Leader | Drive preclinical discovery programs to move swiftly into early development at Addition Therapeutics.
Where is Daniel Boden, Md based?
Daniel Boden, Md is based in San Francisco Bay Area, United States while working with Addition Therapeutics.
What companies has Daniel Boden, Md worked for?
Daniel Boden, Md has worked for Addition Therapeutics, The Janssen Pharmaceutical Companies Of Johnson & Johnson, Aaron Diamond Aids Research Center, Rockefeller University, Brown University, and Humboldt University Of Berlin.
How can I contact Daniel Boden, Md?
You can use AeroLeads to view verified contact signals for Daniel Boden, Md at Addition Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Daniel Boden, Md attend?
Daniel Boden, Md holds Doctor Of Medicine (Md) from University Of Düsseldorf.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trialCheck these profiles if this is not the Daniel Boden, Md you were looking for.
View similar profiles